Nidek Clarifies Position in Anti-competitive Environment
Also check out:
EC-5000 Product Info
We would like to take a few minutes to clarify some issues with the professional ophthalmic community regarding: our commitment to providing quality instrumentation to American surgeons; our position on patents and per-procedure fees; and the introduction of competition into an anti-competitive environment.
Nidek is committed to providing American surgeons with quality instrumentation. Presently, there are over 25 Nidek products available in the United States ophthalmic industry, including high-caliber surgical, diagnostic, and laser equipment. Nidek has nearly 30 years experience in this highly specialized field. We attribute a large measure of our success to working closely with physicians to design products to their specifications, employing high quality components, ease-of-use, and effective customer support.
We have invested much time, effort and money in the FDA Market Approval process of the Nidek EC-5000 Excimer Laser System since 1994. The EC-5000 is now FDA Approved for PRK of mild to moderate myopia, and available for sale in the United States. Our excimer laser is proven, state-of-the-art, scanning technology, with hundreds of systems placed worldwide. We are committed to continuing our efforts to allow your patients to benefit from this next generation laser.
Patents and Per-Procedure Fees
Nidek believes in the rights of a company to protect its technology with patents. We believe that we do not infringe the technology of competing excimer laser companies. Recent lawsuits have strengthened our position with victories in the United Kingdom and Japan. These cases have demonstrated that our technology has not infringed that of others. In the United Kingdom, one of the asserted patents was, in fact, found to be invalid.
We also believe that licensing of patents should be settled company-to-company, and not result in per-procedure costs that burden the end user. Nidek has not, and does not intend to, charge a per-procedure fee for any of our technology. We hold our own patents, and in addition, have purchased the rights to the IBM patents on excimer technology internationally. In the United States, we have pre-paid licensing fees for these patents. These patents were purchased for a price of $7.5 million. We will not charge the end user of our laser to recover that cost.
Nidek believes in fair competition and offering today's refractive surgeons a choice in the instrumentation that they use to treat their patients. Current trade practices of our competitors are under review by the Federal Trade Commission.
We do not believe in companies involving end users in litigation to force them into buying a product. Nidek is a privately held company and is not driven by the value of it's stock on the public market. Our goal is to provide a high-quality excimer laser to American physicians at a reasonable cost.
For more information on the Nidek EC-5000 Excimer Laser System, or any of the Nidek family of ophthalmic products, please contact Nidek Inc. 800-223-9044. For legal and clinical study information, please contact Nidek Technologies Inc. 626-578-1351.
© Copyright 1999 Nidek